# Immunome

Source: https://onco.cc/companies/immunome/  
OnCo record `immunome` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunome is a US biotechnology company whose lead drug varegacestat, a gamma-secretase inhibitor acquired with Ayala Pharmaceuticals, completed the phase 3 RINGSIDE trial in progressing desmoid tumours; it also develops antibody-drug conjugates.

## Summary

Immunome, headquartered in Bothell, Washington, develops targeted cancer therapies. Its most advanced programme is varegacestat (AL102), an oral gamma-secretase inhibitor that blocks Notch signalling and was tested against placebo in the phase 3 RINGSIDE trial in adults and adolescents with progressing desmoid tumours; the programme came with the acquisition of Ayala Pharmaceuticals' assets. The company also develops antibody-drug conjugates from its own antibody discovery platform. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Immunome, Inc.; Ayala Pharmaceuticals
- Tags: ctgov-sponsor
- HQ: Bothell, WA
- Type: biotech
- Website: https://immunome.com/

## Sources

- Official website: https://immunome.com/
- ClinicalTrials.gov: trials led by Immunome: https://clinicaltrials.gov/search?lead=Immunome

## Connected records

- cancers: [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [Gamma-secretase (PSEN1)](https://onco.cc/targets/gamma-secretase/)
- drugs: [Varegacestat](https://onco.cc/drugs/varegacestat/)
- trials: [A Study of AL102 in Patients With Progressing Desmoid Tumors](https://onco.cc/trials/nct04871282/)

---
JSON: https://onco.cc/api/v1/entities/immunome.json